Sequential Therapy for Hypogonadotropic Hypogonadism
Sequential Therapy for Hypogonadotropic Hypogonadism
The traditional therapy for induction of spermatogenesis in male hypogonadotropic
 hypogonadism requires both HCG and human menopausal gonadotropin (HMG) or FSH until pregnancy
 occurs. Because of the high cost of hMG or FSH preparations and poor compliance, the
 investigators raise a new sequential therapeutic approach which can make the treatment more
 economic and tolerable. The zinc supplement will be also evaluated in patients in this study.
 This randomized, parallel, open, and multi-center study will compare the efficacy of
 traditional therapy with new therapy and evaluate the safety of the new protocol.
Inclusion Criteria:

 -  Clinical hypogonadotropic hypogonadism

 -  Hormonal levels: Testosterone < 1.8ng/ml, LH < 2-3 mIU/mL and FSH < 2-3 mIU/mL

 -  Infantile testis

 -  Delayed bone age

 -  Normal testing of the anterior pituitary gland

 Exclusion Criteria:

 -  Prior therapy with HMG or FSH

 -  Severe dysfunction of live and kidney

 -  Cryptorchidism or no response to HCG stimulation experiment (Testosterone < 1.8ng/ml
 after HCG stimulation)

 -  Another pituitary hormonal deficiency

 -  Hypergonadotropic hypogonadism

 -  With abnormal karyotype